Categories: Technology

Parker Increases Quarterly Cash Dividend 11% to $2.00 per Share

 | Source: Parker-Hannifin Corporation


CLEVELAND, April 23, 2026 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that its Board of Directors has declared a quarterly cash dividend of $2.00 per share of common stock to shareholders of record as of May 8, 2026. The dividend is payable June 5, 2026. The dividend represents an 11% increase over the previous quarterly cash dividend of $1.80 per common share and will be the 304th consecutive quarterly dividend paid by the company.

“This increase in our quarterly dividend reflects the Board’s confidence in our consistent cash flow generation and long-term outlook,” said Jenny Parmentier, Chairman and Chief Executive Officer. “We remain committed to active capital deployment through acquisitions, share repurchases and maintaining our track record of increasing our annual dividend payout, which now stands at 70 consecutive fiscal years.”

Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For more than a century the company has been enabling engineering breakthroughs that lead to a better tomorrow. Parker has increased its annual dividend per share paid to shareholders for 70 consecutive fiscal years, among the top five longest-running dividend-increase records in the S&P 500 index. Learn more at www.parker.com or @parkerhannifin.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Often but not always, these statements may be identified from the use of forward-looking terminology such as “anticipates,” “believes,” “may,” “should,” “could,” “expects,” “targets,” “is likely,” “will,” or the negative of these terms and similar expressions, and may also include statements regarding future performance, orders, earnings projections, events or developments. Parker cautions readers not to place undue reliance on these statements. It is possible that the future performance may differ materially from expectations, including those based on past performance.

Among other factors that may affect future performance are: changes in business relationships with and orders by or from major customers, suppliers or distributors, including delays or cancellations in shipments; disputes regarding contract terms, changes in contract costs and revenue estimates for new development programs; changes in product mix; ability to identify acceptable strategic acquisition targets; uncertainties surrounding timing, successful completion or integration of acquisitions and similar transactions, including the pending acquisition of Filtration Group Corporation and the integration of Curtis Instruments, Inc.; ability to successfully divest businesses planned for divestiture and realize the anticipated benefits of such divestitures; the determination and ability to successfully undertake business realignment activities and the expected costs, including cost savings, thereof; ability to implement successfully business and operating initiatives, including the timing, price and execution of share repurchases and other capital initiatives; availability, cost increases of or other limitations on our access to raw materials, component products and/or commodities if associated costs cannot be recovered in product pricing; ability to manage costs related to insurance and employee retirement and health care benefits; legal and regulatory developments and other government actions, including related to environmental protection, and associated compliance costs; supply chain and labor disruptions, including as a result of tariffs and labor shortages; threats associated with international conflicts and cybersecurity risks and risks associated with protecting our intellectual property; uncertainties surrounding the ultimate resolution of outstanding legal proceedings, including the outcome of any appeals; effects on market conditions, including sales and pricing, resulting from global reactions to U.S. trade policies; manufacturing activity, air travel trends, currency exchange rates, difficulties entering new markets and economic conditions such as inflation, deflation, interest rates and credit availability; inability to obtain, or meet conditions imposed for, required governmental and regulatory approvals; changes in the tax laws in the United States and foreign jurisdictions and judicial or regulatory interpretations thereof; and large scale disasters, such as floods, earthquakes, hurricanes, industrial accidents and pandemics. Readers should also consider forward-looking statements in light of risk factors discussed in Parker’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025 and other periodic filings made with the SEC.

###




Contact Data

              Contact: Media – Aidan Gormley, Director, Global Communications and Branding 216/896-3258 aidan.gormley@parker.com  Financial Analysts – Jeff Miller, Vice President, Investor Relations  216/896-2708 jeffrey.miller@parker.com               

GlobeNews Wire

Recent Posts

Nikon Metrology Receives Frost & Sullivan’s 2026 Global Product Leadership Recognition for Excellence in Laser Radar BIW Inspection

Recognized for advancing high-precision, in-line dimensional inspection and enabling data-driven manufacturing transformation in automotive productionSAN…

3 hours ago

GIGABYTE Opens COMPUTEX 2026 with ENTER INFINITY, Where AI, Gaming, and PC Innovation Unite

TAIPEI, June 2, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, today officially opened…

3 hours ago

GIGABYTE Unveils Award-Winning AI Gaming Laptops and Revolutionary GiMATE Updates at COMPUTEX 2026

TAIPEI, June 2, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its AI…

3 hours ago

Stamus Networks Marks 10th Year Supporting NATO CCDCOE Cyber Defense Exercises

Company celebrates a decade of supporting the world's premier live-fire cyber defense exercises with expertise,…

4 hours ago

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+…

6 hours ago

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed…

6 hours ago